双途径介入疗法治疗原发性肝癌疗效评价

目的　探讨双途径介入疗法 (下称双介入法 )治疗原发性肝癌的临床价值。方法　选择原发性肝癌患者 6 5例 ,对其中 34例单纯行肝动脉化疗栓塞 (TACE,对照组 ) ,31例行 TACE和分次多点经皮肝穿刺注射无水乙醇 (双介入法 ,观察组 )。全部病例定期做 CT检查和 AFP测定 ,观察肿瘤客观疗效。结果　对照组及观察组肿瘤客观有效率 (CR+PR)分别为 35 .3%、6 4 .4 % (P<0 .0 5 ) ;AFP下降幅度分别为 5 6 .1%、78.6 % (P<0 .0 5 ) ;2年存活率分别为 5 0 %、6 1.3% (P<0 .0 5 )。结论　双介入法治疗原发性肝癌疗效肯定 ,优于单纯应用 TACE。

Value of the combined application of transcatheter hepatic artery chemoembolization and percutaneous ethanol injection in the treatment of hepatocellular carcinoma

Objective To evaluate the clinical value of the combined application of transcatheter hepatic artery chemoembolization(TACE)and percutaneous ethanol injection(PEI)in the treatment of hepatocellular carcinoma(HCC).Methods 65 HCC patients were treated with interventional methods,among which 34 cases were treated with TACE alone(group 1) and 31 cases were treated with combined TACE and PEI(group 2).To observe the objective results,all patients were examined by CT and determined by AFP.Results The CR+PR in group 1 was 35.3%,the decline rate of the AFP was 56.1% and 2-year survival rate was 50%.While above items in group 2 were 64.5%,87.6% and 61.3% respectively(P<0.05).Conclusion It is certain that the combined application of TACE and PEI to treat HCC is much better than TACE alone.